Clinical Trial Search

Primary: Number of Participants With Composite Neonatal Morbidity — 149; 163; 62; 55 Participants — p=0.14

Primary: Percent Change in Plasma Triglycerides — -2.0; 16.0; -5.0; -5.0 percent change

Primary: Change in E to A Ratio — 1.04; 1.25 Ratio — p=<0.01

Primary: Normalization of Glucose Levels — 9; 2; 4 Participants — p=.035

Primary: Total and First Phase of Insulin Secretion (Insulinogenic Index and Stumvoll Index) After 90 Days — 0.41; 0.23; 1135.7; 309.0 index

Primary: Neuropathic Pain — 482; 461; 560 Participants

Primary: Change in the Frequency of Hyper- and Hypo-glycemic Events From Baseline to Week 8-12. — -18; -7.5 Events

Primary: Frequency of Eating in Response to Cravings (Primary Mechanistic Outcome) — -20.39; -25.27 % of EMAs with craving related eating

Primary: Change From Baseline for Mean Hemoglobin A1c (HbA1C) — 6.9; -0.5 Percent of glycosylated hemoglobin

Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies

Primary: The Change From Baseline of DQ8 Antigen Presentation by Peripheral Blood Mononuclear Cells After 6 Weeks of Methyldopa Treatment. — 642; 430; 27.4; 17.9 pg/mL

Primary: Fasting Plasma Glucose — 77.4; 77.7 mmol/L

Primary: The Percentage Change in HbA1c Level From Baseline to 12 Weeks — -11.1; 0.0 percentage change

Primary: Change in Weight From Baseline at 12 Months or More — -8.37 Kg — p=<0.05

Primary: Disposition Index — 0.023; 0.149 index

Primary: ISR in Response to a Glucose Clamp and Oral Glucose Ingestion Before and After 2 Months of Insulin Treatment to Improve Average Glycemia. — 0.67; 0.75; 1.11; 0.76 pmol/min

Primary: Changes in LDL Cholesterol — -0.83; -1.47; -0.93; -0.32 mmol/L

Primary: Δ Mean AUC (Area Under the Curve) Plasma [Glucose] — -17.7; 54.9 mmol.min.L-1

Primary: Abnormal Glucose Levels After Colonoscopic Preparation — 2; 0; 185 Participants

Primary: Change From Baseline in A1C at Week 18 — -1.00; 0.02 Percent — p=<0.001

Primary: Blood Glucose Levels — 5.6; 5.7; 6.7; 7.7 mmol/L — p=<0.001

Primary: Beta-cell Function - C-peptide AUC (Area Under the Curve) — 2096; 1725 ng*min/mL

Primary: Radiographic Bone Level — 2.69; 2.54 mm

Primary: Change in HbA1c — -0.25; -0.4 Percent — p=0.2539

Primary: Sleep Efficiency — 79.5; 83.1 Percentage of time asleep — p=0.04

Primary: Total Physical Activity Log Means and Geometric Means With Standard Deviation in Intervention and Control Groups After Intervention. — 216.07; 201.47 log calories/day…

Primary: Glycemic Index — 76.79; 86.92 percentage of AUC from GI100 — p=0.005

Primary: Glycosylated Hemoglobin Change — 6.82; 7.17; 6.80; 6.33 percentage of glycosylated hemoglobin — p=0.830

Primary: Hemoglobin A1c Levels — 7.1; 7.1 percent — p=0.67

Primary: Number of Children With Documented Risk Factors for Type 2 Diabetes — 283; 282 Participants